During the last session, Third Harmonic Bio Inc (NASDAQ:THRD)’s traded shares were 0.63 million, with the beta value of the company hitting 2.73. At the end of the trading day, the stock’s price was $3.60, reflecting an intraday gain of 4.96% or $0.17. The 52-week high for the THRD share is $16.94, that puts it down -370.56 from that peak though still a striking 11.67% gain since the share price plummeted to a 52-week low of $3.18. The company’s market capitalization is $162.21M, and the average intraday trading volume over the past 10 days was 2.05 million shares, and the average trade volume was 540.17K shares over the past three months.
Third Harmonic Bio Inc (THRD) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.20. THRD has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.33.
Third Harmonic Bio Inc (NASDAQ:THRD) trade information
Third Harmonic Bio Inc (THRD) registered a 4.96% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.96% in intraday trading to $3.60, hitting a weekly high. The stock’s 5-day price performance is -25.77%, and it has moved by -40.00% in 30 days. Based on these gigs, the overall price performance for the year is -61.08%. The short interest in Third Harmonic Bio Inc (NASDAQ:THRD) is 3.57 million shares and it means that shorts have 12.68 day(s) to cover.
The consensus price target of analysts on Wall Street is $19, which implies an increase of 81.05% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.6 and $23 respectively. As a result, THRD is trading at a discount of -538.89% off the target high and 0.0% off the low.
While earnings are projected to return -47.12% in 2025, the next five years will return -6.04% per annum.
THRD Dividends
Third Harmonic Bio Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Third Harmonic Bio Inc (NASDAQ:THRD)’s Major holders
Third Harmonic Bio Inc insiders own 9.13% of total outstanding shares while institutional holders control 99.13%, with the float percentage being 109.09%. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the largest shareholder of the company, while 116.0 institutions own stock in it. As of 2024-06-30, the company held over 10.91 million shares (or 26.8961% of all shares), a total value of $141.8 million in shares.
The next largest institutional holding, with 5.78 million shares, is of ORBIMED ADVISORS LLC’s that is approximately 14.2498% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $75.13 million.
Also, the Mutual Funds coming in first place with the largest holdings of Third Harmonic Bio Inc (THRD) shares are Price (T.Rowe) Small-Cap Value Fund and Fidelity Select Portfolios – Health Care . Data provided on Sep 30, 2024 indicates that Price (T.Rowe) Small-Cap Value Fund owns about 846.79 shares. This amounts to just over 1.88 percent of the company’s overall shares, with a $3.05 million market value. The same data shows that the other fund manager holds slightly less at 680.0, or about 1.51% of the stock, which is worth about $2.45 million.
